目的：评价力尔凡合并化、放疗治疗肿瘤患者的初步疗效和安全性，同时观察对患者免疫功能的影响。方法：157例恶性肿瘤患者，男84例，女73例；分小细胞肺癌（SCLC）、晚期乳腺癌（ABC）和非霍奇金淋巴瘤（NHL）化疗组及非小细胞肺癌（NSCLC）放疗组等4组，每组再随机分为力尔凡治疗组和对照组。结果：近期疗效：小细胞肺癌、晚期乳腺癌和非霍奇金淋巴瘤化疗治疗组的有效率分别为63．2％、71．4％和85．7％；对照组分别为41．2％、42．1％和63．2％，各化疗治疗组与对照组之间均有显著性差异。放疗治疗组有效率为57．1％，而对照组为20％，两组亦有显著性差异。免疫功能：力尔凡治疗组疗后PPD试验阳性率、NK细胞数、T细胞总数均有明显上升，T_8细胞数治疗组疗后则下降，CD_4／CD_8治疗组疗后亦有一定程度地升高。力尔凡治疗组白细胞下降幅度明显低于对照组。发热、消化道等毒副反应治疗组与对照组之间无显著性差异。结论：本组资料说明力尔凡在一定程度上可增强化、放疗的抗肿瘤作用，提高患者的免疫功能，对抗化、放疗所致的白细胞下降，临床使用耐受性良好。 OBJECTIVE: To evaluate the initial efficacy and safety of Lerfan’s combination of radiation therapy and radiotherapy for cancer patients, and to observe the effect on patient’s immune function. Methods: 157 patients with malignant tumors, 84 males and 73 females; small cell lung cancer (SCLC), advanced breast cancer (ABC) and non-Hodgkin lymphoma (NHL) chemotherapy group and non-small cell lung cancer (NSCLC) Radiotherapy group and other 4 groups, each group were randomly divided into the Lerfan treatment group and the control group. Results: The short-term efficacy: The effective rates for the small cell lung cancer, advanced breast cancer, and non-Hodgkin’s lymphoma chemotherapy groups were 63.2%, 71.4%, and 85.7%, respectively; the control group was 41.2%. , 42.1% and 63.2%, there was a significant difference between each chemotherapy treatment group and the control group. The effective rate in the radiotherapy group was 57.1%, compared with 20% in the control group. There was also a significant difference between the two groups. Immune function: After treatment, the positive rate of PPD test, the number of NK cells and the total number of T cells increased significantly in the treatment group. The number of T_8 cells in the treatment group decreased after treatment, and the CD_4/CD_8 treatment group also increased to some extent after treatment. high. The decrease in leukopenia in the treatment group was significantly lower than that in the control group. There was no significant difference between the treatment group and the control group such as fever and digestive tract. Conclusion: This group of data shows that, to a certain extent, Leerfan can enhance the anti-tumor effect of chemotherapy and radiotherapy, improve the patient’s immune function, anti-chemotherapy, radiotherapy-induced leukopenia, and good clinical tolerability.